Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Med Sci Monit ; 23: 1055-1063, 2017 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-28240997

RESUMO

BACKGROUND This study sought to compare the 30-day and 1-year survival of patients diagnosed with ST-segment elevation myocardial infarction (STEMI), whose symptom onset to in-hospital first medical contact (IHFMC) was 3-6 h, who received either in-hospital thrombolysis (IHT) in the nearest county hospital or direct transfer to a larger hospital in Henan province, China for primary percutaneous coronary intervention (PPCI). MATERIAL AND METHODS Patients were allocated into 2 groups: one group received IHT in the local county hospital, whereas the other group were transferred to the PCI centers to receive PPCI. Patient demographic data, baseline characteristics, and time between different stages of patient contact to the initiation of treatment for IHT or PPCI were recorded for analysis. RESULTS No significant difference was identified between the 2 groups with the baseline characteristics and demographic data. The all-cause mortality was not significantly different between the IHT and PPCI group at 30 days (13.0% vs. 9.9%, p=0.386). However, a significant difference in mortality between the IHT and PPCI group was observed at 1 year (23.4% vs. 14.1%, p=0.035). Inter-hospital transfer time for PPCI tended to be the independent predictor for survival (OR: 4.4 CI 95%: 1.9-14.5, p 0.001). Overall, the patients undergoing PPCI in inter-hospital transfer had a higher survival rates for 1 year compared with patients receiving IHT. CONCLUSIONS Despite the delay associated with inter-hospital transfer for PPCI, patients with STEMI 3-6 h after symptom onset have improved survival with PPCI over patients treated locally with IHT.


Assuntos
Infarto do Miocárdio/mortalidade , Transferência de Pacientes/estatística & dados numéricos , Intervenção Coronária Percutânea/mortalidade , Infarto do Miocárdio com Supradesnível do Segmento ST/mortalidade , Terapia Trombolítica/mortalidade , Angioplastia Coronária com Balão , China , Feminino , Hospitais Comunitários , Humanos , Masculino , Pessoa de Meia-Idade , Intervenção Coronária Percutânea/métodos , Estudos Retrospectivos , Taxa de Sobrevida , Terapia Trombolítica/métodos , Tempo para o Tratamento
2.
Int Immunopharmacol ; 28(1): 525-30, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26218278

RESUMO

It has been demonstrated that the circadian clock system could be a potential factor involved in inflammation and the progression of atherosclerosis. A previous study has reported that cryptochrome 1 (CRY1), which is a core clock component, is associated with regulating proinflammation. However, whether CRY1 is involved in atherosclerosis is currently unknown. In the present study, we aimed to explore the role of CRY1 in regulating atherosclerosis in apolipoprotein E (ApoE)-deficient mice and the underlying molecular mechanism. We found that CRY1 mRNA expression was significantly decreased in atherosclerotic patients compared to the healthy subjects. Overexpression of CRY1 in the mouse model of atherosclerosis by adenovirus-mediated gene transfer significantly decreased the expression of proinflammatory factors including tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, and macrophage inflammatory protein-1α (MIP-1α). In addition, the adhesion molecules including vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin, were also downregulated by CRY1 overexpression. Furthermore, the plaque area of the aortic sinus and the concentrations of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) were also decreased in the atherosclerotic mice by CRY1 overexpression. Moreover, overexpression of CRY1 significantly decreased the protein levels of toll-like receptor (TLR) 2, TLR4 and phosphorylated p65 (p-p65). Additionally, the results of luciferase reporter assay exhibited that CRY1 overexpression was capable of inhibiting the activation of nuclear factor-kappa B (NF-κB). Taken together, our results suggest that overexpression of CYR1 relieves the development of atherosclerosis that may be associated with regulating the TLR/NF-κB pathway.


Assuntos
Aterosclerose/metabolismo , Criptocromos/metabolismo , Animais , Apolipoproteínas E/genética , Aterosclerose/sangue , Células Cultivadas , Criptocromos/genética , Citocinas/sangue , Células Endoteliais , Humanos , Masculino , Camundongos , Camundongos Knockout , Músculo Liso Vascular , Miócitos de Músculo Liso/metabolismo , NF-kappa B/metabolismo , RNA Mensageiro/metabolismo , Receptor 2 Toll-Like/metabolismo , Receptor 4 Toll-Like/metabolismo
3.
Clin Cardiol ; 35(9): 559-64, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22740086

RESUMO

BACKGROUND: Both the Tpeak-Tend interval (Tp-e) and the Tp-e/QT ratio have been linked to increased risk for arrhythmia. Patient Tp-e/QT ratios were investigated prior to primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation myocardial infarction (STEMI). HYPOTHESIS: Tp-e/QT ratio maybe associated with the prognosis in patients with ST-segment elevation. METHODS: A total of 338 patients (N = 338) with STEMI treated by pPCI were included. The Tp-e and Tp-e/QT ratio were determined using electrocardiograms in the subjects exhibiting ST-segment elevation. RESULTS: The Tp-e/QT ratio was correlated with both short- and long-term outcomes. Analysis of the receiver operating characteristic curve demonstrated that the optimal cutoff value for outcome prediction was a Tp-e/QT ratio of 0.29. Of the 388 patients enrolled, 115 (34.0%) exhibited a Tp-e/QT ratio ≥ 0.29. Patients with a Tp-e/QT ratio ≥ 0.29 showed elevated rates of both in-hospital death (21.9% vs 2.3%; P < 0.001) and main adverse cardiac events (MACE) (48.1% vs 15.3%; P < 0.005). After discharge, Tp-e/QT ratios ≥ 0.29 remained an independent predictor of all-cause death (35.5% vs 5.2%, P < 0.001) and cardiac death (32.3% vs 2.6%, P < 0.001). CONCLUSIONS: The Tp-e/QT ratio may serve as a prognostic predictor of adverse outcomes after successful pPCI treatment in STEMI patients.


Assuntos
Eletrocardiografia , Infarto do Miocárdio/terapia , Intervenção Coronária Percutânea , Adulto , Idoso , Causas de Morte , Feminino , Seguimentos , Mortalidade Hospitalar , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/mortalidade , Infarto do Miocárdio/fisiopatologia , Intervenção Coronária Percutânea/efeitos adversos , Intervenção Coronária Percutânea/métodos , Prognóstico , Fatores de Risco , Taxa de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA